NEW YORK (GenomeWeb) – Horizon Discovery Group today announced an agreement to buy the CombinatoRx Service business of biopharmaceutical firm Zalicus for £4.74 million ($8.0 million).

CombinatoRx provides combination high-throughput screening (cHTS) services. Upon completion of the deal it will operate as a wholly owned subsidiary of Horizon and be called Horizon CombinatoRx. The new company will be located in a 23,000-square-foot facility in Cambridge, Mass.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.